Acceleron Inks $498M Pact with Shire for Lead Muscle Drug

Acceleron partners with Shire to develop its muscle enhancing drug, ACE-031, currently in a Phase IIa efficacy trial for Duchenne Muscular Dystrophy. ACE-031 acts by inhibiting the activin receptor type IIB and may preserve muscle strength in a broad category of muscle wasting diseases including ALS. This therapeutic target may even extend survival, as suggested by a related drug study in a mouse model of cachexia (see Nature News: http://www.nature.com/news/2010/100819/full/news.2010.419.html).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail